217 related articles for article (PubMed ID: 27101548)
1. Time and tumor type (primary or metastatic) do not influence the detection of BRAF/NRAS mutations in formalin fixed paraffin embedded samples from melanomas.
Potrony M; Badenas C; Naerhuyzen B; Aguilera P; Puig-Butille JA; Tell-Marti G; Díaz A; Carrera C; Alos L; Delahaye N; Malvehy J; Puig S
Clin Chem Lab Med; 2016 Nov; 54(11):1733-1738. PubMed ID: 27101548
[TBL] [Abstract][Full Text] [Related]
2. Prospective evaluation of two screening methods for molecular testing of metastatic melanoma: Diagnostic performance of BRAF V600E immunohistochemistry and of a NRAS-BRAF fully automated real-time PCR-based assay.
Vallée A; Denis-Musquer M; Herbreteau G; Théoleyre S; Bossard C; Denis MG
PLoS One; 2019; 14(8):e0221123. PubMed ID: 31415669
[TBL] [Abstract][Full Text] [Related]
3. Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma.
Thomas NE; Edmiston SN; Alexander A; Groben PA; Parrish E; Kricker A; Armstrong BK; Anton-Culver H; Gruber SB; From L; Busam KJ; Hao H; Orlow I; Kanetsky PA; Luo L; Reiner AS; Paine S; Frank JS; Bramson JI; Marrett LD; Gallagher RP; Zanetti R; Rosso S; Dwyer T; Cust AE; Ollila DW; Begg CB; Berwick M; Conway K;
JAMA Oncol; 2015 Jun; 1(3):359-68. PubMed ID: 26146664
[TBL] [Abstract][Full Text] [Related]
4. NRAS (Q61R), BRAF (V600E) immunohistochemistry: a concomitant tool for mutation screening in melanomas.
Uguen A; Talagas M; Costa S; Samaison L; Paule L; Alavi Z; De Braekeleer M; Le Marechal C; Marcorelles P
Diagn Pathol; 2015 Jul; 10():121. PubMed ID: 26204954
[TBL] [Abstract][Full Text] [Related]
5. Integrated routine workflow using next-generation sequencing and a fully-automated platform for the detection of KRAS, NRAS and BRAF mutations in formalin-fixed paraffin embedded samples with poor DNA quality in patients with colorectal carcinoma.
Franczak C; Dubouis L; Gilson P; Husson M; Rouyer M; Demange J; Leroux A; Merlin JL; Harlé A
PLoS One; 2019; 14(2):e0212801. PubMed ID: 30811471
[TBL] [Abstract][Full Text] [Related]
6. NRAS mutations are more prevalent than KIT mutations in melanoma of the female urogenital tract--a study of 24 cases from the Netherlands.
van Engen-van Grunsven AC; Küsters-Vandevelde HV; De Hullu J; van Duijn LM; Rijntjes J; Bovée JV; Groenen PJ; Blokx WA
Gynecol Oncol; 2014 Jul; 134(1):10-4. PubMed ID: 24802725
[TBL] [Abstract][Full Text] [Related]
7. KIT, NRAS and BRAF mutations in sinonasal mucosal melanoma: a study of 56 cases.
Zebary A; Jangard M; Omholt K; Ragnarsson-Olding B; Hansson J
Br J Cancer; 2013 Aug; 109(3):559-64. PubMed ID: 23860532
[TBL] [Abstract][Full Text] [Related]
8. Mutation scanning of BRAF, NRAS, KIT, and GNAQ/GNA11 in oral mucosal melanoma: a study of 57 cases.
Lyu J; Wu Y; Li C; Wang R; Song H; Ren G; Guo W
J Oral Pathol Med; 2016 Apr; 45(4):295-301. PubMed ID: 26399561
[TBL] [Abstract][Full Text] [Related]
9. [Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation].
Lázár V
Magy Onkol; 2013 Jun; 57(2):96-9. PubMed ID: 23795354
[TBL] [Abstract][Full Text] [Related]
10. Somatic mutation analysis in melanoma using targeted next generation sequencing.
Miraflor AP; de Abreu FB; Peterson JD; Turner SA; Amos CI; Tsongalis GJ; Yan S
Exp Mol Pathol; 2017 Oct; 103(2):172-177. PubMed ID: 28822769
[TBL] [Abstract][Full Text] [Related]
11. KIT, NRAS, BRAF and PTEN mutations in a sample of Swedish patients with acral lentiginous melanoma.
Zebary A; Omholt K; Vassilaki I; Höiom V; Lindén D; Viberg L; Kanter-Lewensohn L; Johansson CH; Hansson J
J Dermatol Sci; 2013 Dec; 72(3):284-9. PubMed ID: 23993026
[TBL] [Abstract][Full Text] [Related]
12. Clinical performance evaluation of the Idylla NRAS-BRAF mutation test on retrospectively collected formalin-fixed paraffin-embedded colorectal cancer tissue.
Johnston L; Power M; Sloan P; Long A; Silmon A; Chaffey B; Lisgo AJ; Little L; Vercauteren E; Steiniche T; Meyer T; Simpson J
J Clin Pathol; 2018 Apr; 71(4):336-343. PubMed ID: 28899979
[TBL] [Abstract][Full Text] [Related]
13. Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma.
Colombino M; Lissia A; Capone M; De Giorgi V; Massi D; Stanganelli I; Fonsatti E; Maio M; Botti G; Caracò C; Mozzillo N; Ascierto PA; Cossu A; Palmieri G
J Transl Med; 2013 Aug; 11():202. PubMed ID: 23987572
[TBL] [Abstract][Full Text] [Related]
14. The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort.
Ekedahl H; Cirenajwis H; Harbst K; Carneiro A; Nielsen K; Olsson H; Lundgren L; Ingvar C; Jönsson G
Br J Dermatol; 2013 Nov; 169(5):1049-55. PubMed ID: 23855428
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of a Rapid, Fully Automated Platform for Detection of BRAF and NRAS Mutations in Melanoma.
Barel F; Guibourg B; Lambros L; Le Flahec G; Marcorelles P; Uguen A
Acta Derm Venereol; 2018 Jan; 98(1):44-49. PubMed ID: 28660280
[TBL] [Abstract][Full Text] [Related]
16. Droplet Digital PCR for Mutation Detection in Formalin-Fixed, Paraffin-Embedded Melanoma Tissues: A Comparison with Sanger Sequencing and Pyrosequencing.
McEvoy AC; Wood BA; Ardakani NM; Pereira MR; Pearce R; Cowell L; Robinson C; Grieu-Iacopetta F; Spicer AJ; Amanuel B; Ziman M; Gray ES
J Mol Diagn; 2018 Mar; 20(2):240-252. PubMed ID: 29305225
[TBL] [Abstract][Full Text] [Related]
17. BRAF(V600E) and NRAS(Q61L/Q61R) mutation analysis in metastatic melanoma using immunohistochemistry: a study of 754 cases highlighting potential pitfalls and guidelines for interpretation and reporting.
Kakavand H; Walker E; Lum T; Wilmott JS; Selinger CI; Smith E; Saw RP; Yu B; Cooper WA; Long GV; O'Toole SA; Scolyer RA
Histopathology; 2016 Oct; 69(4):680-6. PubMed ID: 27151331
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of BRAF mutation testing methodologies in formalin-fixed, paraffin-embedded cutaneous melanomas.
Lade-Keller J; Rømer KM; Guldberg P; Riber-Hansen R; Hansen LL; Steiniche T; Hager H; Kristensen LS
J Mol Diagn; 2013 Jan; 15(1):70-80. PubMed ID: 23159593
[TBL] [Abstract][Full Text] [Related]
19. BRAF/NRAS wild-type melanomas have a high mutation load correlating with histologic and molecular signatures of UV damage.
Mar VJ; Wong SQ; Li J; Scolyer RA; McLean C; Papenfuss AT; Tothill RW; Kakavand H; Mann GJ; Thompson JF; Behren A; Cebon JS; Wolfe R; Kelly JW; Dobrovic A; McArthur GA
Clin Cancer Res; 2013 Sep; 19(17):4589-98. PubMed ID: 23833303
[TBL] [Abstract][Full Text] [Related]
20. Standardized fixation process is crucial to permit molecular analyses in formalin-fixed and paraffin-embedded melanoma samples.
Uguen A; Guibourg B; Guéguen P
Clin Chem Lab Med; 2016 Nov; 54(11):e359-e360. PubMed ID: 27289004
[No Abstract] [Full Text] [Related]
[Next] [New Search]
